Avid Bioservices Inc (CDMO)

[entdoc]

Most amazing is that we are just scratching the surface (no pun) an anti-phospholipid (surface)MAB-technology, and PPHM has a enviable lead in human testing. More important, PPHM has the proprietary MAB recipe(s), and the FDA approved MAB manufacturing facility for production. If trial numbers are good as we think there is no reason why PPHM cannot go it alone. Almost as important to the investment community for future biotech developments are the several roadblocks and detours encountered in the gene therapy field in the past few months. It does not look as if the MAB approach to disease is going to be supplanted by that tech in the near future. Cheers, and congratulations to PPHM Tustin,Phil Thorpe,PhD, and UTSW Dept. Pharmacology!